Navigation Links
MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs
Date:1/13/2009

    MEMOTEXT(R) Personalized Adherence Interventions Incorporated into
    First-of-its-Kind Study Funded by Microsoft HealthVault Be Well Fund

BETHESDA, MD, Jan. 13 /PRNewswire/ - MEMOTEXT announced today that Johns Hopkins University's Wilmer Eye Institute will conduct a clinical trial on patient adherence and clinical outcomes for people with glaucoma using technology developed by MEMOTEXT. The clinical trial, titled "The Impact of Automated Dosing Reminders on Medication Adherence Using HealthVault," is funded by a Microsoft(R) HealthVault(TM) Be Well Fund grant. The 14-month study, to be led by Michael V. Boland, M.D., Ph.D. of the Wilmer Eye Institute, will recruit 500 patients and use telephone calls and text messages in an effort to improve patient outcomes by improving medication adherence.

"We believe this new interface will significantly improve medication adherence in patients with glaucoma," says Amos Adler, President of MEMOTEXT. "It is an honor to collaborate on this special grant, and we are confident this trial will demonstrate that MEMOTEXT's technology-driven adherence solutions can make a significant difference in the lives of patients managing various conditions."

Studies have shown that medication non-adherence costs North America more than $100 billion and 125,000 lives every year. Medication non-adherence impacts all levels of health management, including treatment effectiveness and unnecessary hospitalizations, and almost six percent of all hospital admissions are due to failed patient adherence. Research also indicates that 70% of prescriptions are never consumed and 20% of all new drug prescriptions are never filled for the first time - with adherence rates as low as 10-20% for some disease states.

Approximately 40% of glaucoma patients have difficulty taking their eye drops on a regular basis, resulting in poor care despite an appropriate physician diagnosis and treatment plan. With the Internet and mobile phones so prevalent in patients' lives, they offer new ways to customize a patient adherence regimen. The results of this study should demonstrate MEMOTEXT program's usefulness for glaucoma, as well as the many other chronic diseases where adherence is important.

"Adherence to glaucoma therapy is one of the largest barriers we face in achieving therapeutic success," said glaucoma specialist Donald Budenz, M.D., M.P.H., of the Bascom Palmer Eye Institute in Miami. "We have numerous effective medications to treat this disease, but if patients don't use them, they're not effective. Providing real-time reminders to improve adherence to therapy will be a major step forward in the treatment of chronic diseases such as glaucoma."

The Be Well Fund is designed to stimulate not-for-profit research and development across a broad range of health disciplines that have the potential to significantly improve health and wellness outcomes by seeding innovative avenues of research and exploring the potential for disruptive improvements to health management enabled by re-use and sharing of data among people, families, caregivers, doctors and facilities.

"The Be Well Fund winners share our vision of using the Internet to empower people to fully engage in managing their health and improving health outcomes," said David Cerino, general manager of the Health Solutions Group at Microsoft Corp. "We're excited to help these organizations turn their ideas into reality and to expand the capabilities and services available through HealthVault."

Microsoft received nearly 200 proposals from leading academic and health research organizations across the United States, making it one of the most successful Microsoft Research RFPs in the company's history. Based on the strong interest, Microsoft increased award funding from $3 million to $4.5 million to help bring these proposals to market.

    About "The Impact of Automated Dosing Reminders on Medication Adherence
    using HealthVault" Trial

This clinical trial will be completed in 14 months and in three phases: software development, a clinical research study, and subsequent data analysis. 500 subjects will be recruited in the U.S. for the two-part study, which includes a cohort study to assess baseline adherence with glaucoma medications followed by a randomized, controlled trial of the adherence intervention. Approximately 100 subjects will be randomized to participate in the technology-based adherence intervention program. The results of the study will be presented in a peer-reviewed forum upon completion of the trial, which is expected to conclude in mid-2010.

About Glaucoma and Adherence

Glaucoma is the second leading cause of blindness and visual disability worldwide. It's estimated that 2.5 million people in the U.S. are affected by glaucoma, with another 10 million undiagnosed. By the year 2010, worldwide, the number is predicted to be 60 million. Currently, there is no cure for glaucoma. However, studies have shown that reducing the eye pressure with topical medical therapy, office laser or surgery can prevent occurrence or slow disease progression. The majority of patients diagnosed with glaucoma or ocular hypertension are managed initially with medications. However, despite the availability of effective topical therapies, non-adherence in patients with glaucoma is poor and has been reported between 37-59%.

About MEMOTEXT

MEMOTEXT is a specialized healthcare application service provider focused on providing medication adherence intervention solutions. With over 25 years of expertise in patient-stakeholder issues and the telecommunications industry, MEMOTEXT integrates behavior modification, patient education and live support into the everyday lives of patients. MEMOTEXT uses proven methodologies and customized solutions that support patient efforts to maintain health and lifestyle regimens and comply with prescribed treatment plans. For more information about MEMOTEXT visit www.memotext.com.


'/>"/>
SOURCE MEMOTEXT Personalized Adherence Solutions
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvania Patient Safety Authority Launches New Website and Design With New Tagline Analyzing, Educating and Collaborating for Patient Safety
2. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
3. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
4. Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
5. YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation
6. Johnson Matthey Medical Announces Expansion
7. Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions
8. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
9. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
10. Johns Hopkins and Makerere University to collaborate on African health education initiative
11. Johnson & Johnson Begins Tender Offer to Acquire Omrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" electronic access ... and the Delaware Health Information Network (DHIN) have partnered to improve connectivity of ... health information exchange, DHIN stores and shares real-time health data for more than ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 — 1:30 p.m. ... reduce their regulatory burden? Pay dividends in enhanced and predictable product performance? ...
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, has ... Life Radio network. The episode, which was posted this week, features a 30-minute ... led to Park Cities Pet Sitter’s being awarded the 2017 National Association of Professional ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new ... and contact points to easily connect elderly veterans of America's armed forces to ... funding. It also conveys material on this year's increase in the Veterans Pension ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... WASHINGTON, N.Y. , Feb. 17, 2017 /PRNewswire/ ... firm dedicated to protecting the rights of victims ... problems have prompted regulators to call for better ... in 1990. Safety concerns involving power ... Drug Administration (FDA) to investigate how hospitals report ...
(Date:2/17/2017)... LONDON , February 17, 2017 Cryoablation, ... Urology The global ablation technologies market is expected to ... 9.7% from 2022-2027. The market is expected to grow at a ... at $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, ... drugs based on protein degradation, today announced the presentation ... (AR) PROTAC during a poster session at the American ... GU) in Orlando, FL. ... validate our platform and the potential of PROTACs to ...
Breaking Medicine Technology: